On Monday 19 December, trading started in Acarix AB’s shares at Nasdaq First North Premier in Stockholm. The subscription price was set at 17.60 Swedish crowns per share.

Acarix is a Swedish-Danish medical devices company, specializing in non-invasive and radiation free emergency detection of heart sounds, to prevent coronary heart disease. The company was established in 2009 as a spin-out-company from the Danish Coloplast A/S. Since 2010 the Danish venture capital company Seed Capital and Sunstone Life Science Ventures has financed the development of the company and supported its IPO.

Vator Securities acted as financial advisor and Baker McKenzie acted as legal advisor to Acarix in conjunction with the listing on Nasdaq First North Premier. The principal advisor from Baker McKenzie was Joakim Falkner with support from Johanna Flink, Ian Gulam and Stefan Balazs.

Explore Our Newsroom